Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

July 16, 2019

Recordati to acquire worldwide rights to Signifor and Osilodrostat

Recordati announces the signing of an agreement with Novartis for the acquisition of worldwide rights to Signifor and Signifor LAR for the treatment of Cushing’s disease and acromegaly in adult patients for whom surgery is not an option or for whom surgery has failed.

Recordati to acquire worldwide rights to Signifor and Osilodrostat